Kai Xu

机构：Hefei University of Technology, Wuhan University of Technology, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Ministry of Agriculture, Lianyungang Runzhong Pharmaceutical (China), Brown Foundation, Shanghai Agrobiological Gene Center, The Medical Device (United Kingdom), Ministry of Agriculture and Rural Affairs, The Ohio State University, RMIT University, The University of Texas Health Science Center at Houston · ORCID：0000-0001-5412-6942

发表论文 156 篇 · 总被引 7663 次 · h-index 44

代表论文

• Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants (2024 · Cell Reports · 被引 78)
• Characteristics of JN.1-derived SARS-CoV-2 subvariants SLip, FLiRT, and KP.2 in neutralization escape, infectivity and membrane fusion (2024 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 31)
• Neutralization and Stability of JN.1-derived LB.1, KP.2.3, KP.3 and KP.3.1.1 Subvariants (2024 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 28)
• Neutralization and spike stability of JN.1-derived LB.1, KP.2.3, KP.3, and KP.3.1.1 subvariants (2025 · mBio · 被引 23)
• Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability (2025 · Journal of Virology · 被引 20)
• Immune Evasion, Cell-Cell Fusion, and Spike Stability of the SARS-CoV-2 XEC Variant: Role of Glycosylation Mutations at the N-terminal Domain (2024 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 15)